SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 5B4484) has been filed by GE Silicones,
c/o Hyman, Phelps & McNamara, P.C., 700 13th St. NW., suite 1200, Washington, DC 20005. The petition proposes to amend the food additive regulations in § 177.1520 *Olefin polymers* (21 CFR 177.1520) to provide for the safe use of polymethylsilsesquioxane as a surface lubricant or anti-blocking agent in polyolefin films for use in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before November 16, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: October 3, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–25672 Filed 10–16–95; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETING: The following advisory committee meeting is announced:

Food Advisory Committee and Working Group

Date, time, and place. November 14, 1995, 12:30 p.m., November 15 and 16, 1995, 8:15 a.m., and November 17, 1995, 8:30 a.m., Holiday Inn, Eisenhower Metro Center, 2460 Eisenhower Ave., Alexandria, VA.

Type of meeting and contact person. Open working group committee discussion, November 14, 1995, 12:30 p.m. to 5 p.m.; open public hearing, 5 p.m. to 6 p.m., unless public participation does not last that long; open working group committee discussion, November 15, 1995, 8:15 a.m. to 6 p.m.; open working group committee discussion, November 16, 1995, 8:15 a.m. to 6 p.m.; additional brief opportunities for public hearings may be provided throughout the November 15 and 16, 1995, discussions; open committee discussion, November 17, 1995, 8:30 a.m. to 8:45 a.m.; open public hearing, 8:45 a.m. to 9:45 a.m., unless public participation does not last that long; open committee discussion, 9:45 a.m. to 4 p.m.; Lynn A. Larsen, Center for Food Safety and Applied Nutrition (HFS–5), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–205–4727, or Catherine M. DeRoever, Advisory Committee Staff (HFS–22), 202–205–4251, FAX 202–205–4970, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Food Advisory Committee, code 10564.

General function of the committee. The committee provides advice on emerging food safety, food science, and nutrition issues that FDA considers of primary importance in the next decade.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person by close of business November 8, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. If necessary, comments may be limited to 5 minutes.

Open committee discussion. A working group of the Food Advisory Committee will undertake a scientific discussion of the safety review that has been conducted for olestra for its intended use as a fat replacer in savory snacks. Olestra is a sucrose polyester formed with long chain fatty acids. The working group will be asked to comment on whether all relevant issues associated with olestra have been addressed. The discussion will cover all aspects of the safety review, including nutrient effects and compensation, gastrointestinal tract effects, and labeling. The Food Advisory Committee will discuss the actions and recommendations of its ephedra and olestra working groups, which met on October 11 and 12, 1995, and which are scheduled to meet November 14 through 16, 1995, respectively. The recommendations of the working groups, together with any amendatory comments from the committee, will be formally referred to FDA. More detailed information regarding the meeting agenda that may become available prior to the meeting will be provided to the public via the 800 number given above.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions

for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this Federal Register notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: October 12, 1995.

David A. Kessler,

Commissioner of Food and Drugs.

[FR Doc. 95–25766 Filed 10–12–95; 4:41 pm]

BILLING CODE 4160–01–P

[Docket No. 95N–0281]

''Proceedings of the 1994 Vibrio Vulnificus Workshop;'' Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of ''Proceedings of the 1994 *Vibrio vulnificus* Workshop.'' The workshop was a scientific forum that was cosponsored by FDA, the National Marine Fisheries Service (NMFS), and the Interstate Shellfish Sanitation Conference (ISSC) to: Review the current information available on the epidemiology, ecology, and pathogenicity of *Vibrio vulnificus*, as well as industry practices affecting the levels of this pathogen in seawater and shellfish, ongoing educational efforts, and other related technical information obtained since the last *Vibrio vulnificus* workshop, held in March 1988; identify further critical information needs; and identify the kind of research that will best address these needs using available government and nongovernment resources most effectively.

ADDRESSES: Submit written requests for single copies of ''Proceedings of the 1994 *Vibrio vulnificus* Workshop'' to the Program and Enforcement Branch, Office of Seafood (HFS–417), Food and Drug Administration, 200 C St. SW., Washington, DC 20204. Requests should be identified with the docket number found in brackets in the heading of this document. Send two self-addressed adhesive labels to assist that office in processing your requests. ''Proceedings of the 1994 *Vibrio vulnificus* Workshop'' is available for public examination in the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20875, between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Jeanette B. Lyon, Center for Food Safety and Applied Nutrition, Office of Seafood (HFS–417), 200 C St. SW., Washington, DC 20204, 202–418–3177.

SUPPLEMENTARY INFORMATION: *Vibrio vulnificus* is a naturally-occurring marine bacterium which has been associated with human illness and death from the consumption of raw shellfish, primarily raw oysters. Federal and State government agencies, the ISSC, academia, and the shellfish industry have been monitoring these illnesses and deaths and have focused their research efforts on the development of effective controls to prevent *Vibrio vulnificus*-related illnesses from the consumption of shellfish. In 1988, a jointly sponsored *Vibrio vulnificus* workshop was held in Washington, DC, to identify the current state of knowledge and research needs at that time.

At the 1994 workshop, experts were invited to present scientific and technical updates on the epidemiology, pathogenicity, and ecology of *Vibrio vulnificus*; the effects of time-temperature factors on outgrowth; depuration, irradiation, and other intervening control measures; and the use and effectiveness of consumer education and health advisories. In addition to the invited speakers and representatives of the sponsors, other attendees included state public health officials, industry, consumer representatives, epidemiologists, and researchers. The workshop concluded with several panel discussions during which panel members discussed their views on unresolved information and research needs and mechanisms by which these might be attained.

A draft of the proceedings was published and distributed to the participants for comment in August, 1994. The current publication incorporates their comments.

Dated: September 28, 1995.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–25621 Filed 10–16–95; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Homoharringtonine as an Anticancer Agent

AGENCY: National Institutes of Health, PHS, DHHS.